Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Oncolytic viruses;Immune Checkpoint Therapy
Treatment anti-PD-1
Drugstatus NA
Drugbank ID NA
Checkpoints PD-1
Signature Type Gene
Signature TNFA
Official Symbol TNF
Mode of action TRAN_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental Mouse model
Description We detected an increase in the transcriptional upregulation of genes related to T cell activation, including the T cell costimulatory receptors TNFA and IFNG
PMID 29504948
Title PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy